The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be
| Study Title | A Clinical Trial to Evaluate the Long-term Safety and Durability of Efficacy of BI 3720931, an Inhaled Lentiviral Vector Gene Therapy, After Single Dose Administration in a Previous Clinical Trial, in People With Cystic Fibrosis Rolled-over From a Previous Clinical Trial With BI 3720931 (Lenticlair™-ON) |
|---|---|
| Study Drug | BI 3720931 |
| Type of Study Drug | Genetic therapy |
| Study Phase | 1/2 |
| Study Sponsor | Boehringer Ingelheim |
Link in registry(ies) | https://clinicaltrials.gov/study/NCT06429176 |
| Participating ECFS-CTN sites | Please contact ecfs-ctn@uzleuven.be for most recent sitelist |
| Age | Adult patients |